RBM7 and breast cancer: We further carried out Matrigel tube formation assays and found NF-κB inhibitor PDTC drastically reversed the promotion of HUVEC angiogenesis by conditional medium harvested from RBM7-depleted cells (Figure 6F–G), implying that RBM7-p65 axis may participate in HUVEC angiogenesis through reprogramming the secretome of breast cancer cells.